

Enabling a Southeast Asia Without TB

Johnson & Johnson is collaborating with partners across Southeast Asia to comprehensively address the challenge of tuberculosis in the region and combat antimicrobial resistance



THE CHALLENGE

Most countries in Southeast Asia are ranked highly by the World Health Organization (WHO) in TB burden, including Indonesia, Philippines, Malaysia, Myanmar, Thailand and Vietnam.

WHO estimated that in 2019, there were about 66,000 new cases of multidrug-resistant TB (MDR-TB)/ rifampin-resistant TB (RR-TB) in these 6 countries.¹

However, only 40% (26,784) of these MDR-TB/RR-TB cases were diagnosed and 18,805 were enrolled in treatment in 2019.

To make TB history in Southeast Asia and around the world, it will be essential to accelerate the development and delivery of new innovations and creative solutions to help reach more patients.

ACTION TO END TB

Johnson & Johnson is taking a holistic approach to achieving a Southeast Asia without TB through effective case detection, training health care professionals to better manage TB and MDR-TB, raising awareness of TB and reducing stigma and accelerating affordable access to treatment in collaboration with partners.

Our new treatment, the first medicine with a novel mechanism of action against MDR-TB in more than 40 years, was introduced in the region in 2014. J&J Philippines received first regulatory approval for medicine, followed by Thailand (2017), Indonesia (2018) and Malaysia (2020).

Through the four-year donation program beginning in 2015, more than 15,000 courses of treatment were donated to support patient access across Indonesia, Philippines, Malaysia, Myanmar, Thailand and Vietnam. To ensure sustainable access, J&J Indonesia and Thailand continue to support treatment availability through national reimbursement listing.

Johnson & Johnson also kicked off external partnerships and launched collaborations with various stakeholders including national TB programs, medical associations, health authorities, NGOs and patient associations to enhance awareness, capabilities and technical assistance for DR-TB management in these countries.

These efforts are part of a comprehensive 10-year TB initiative launched by Johnson & Johnson in September 2018. With a focus on treatment access, patient finding and R&D, Johnson & Johnson aims to help save 1.8 million lives and prevent 12 million infections globally over the next decade.

GLOBAL PROGRAM AT A GLANCE



First novel medicine for TB in more than **40 years**; approved in **67 countries**



More than **388K courses of treatment** delivered for MDR-TB patients in **145 countries**, including the 30 highest-burden countries (as of May 2021)




Donating **105K courses of treatment** to eligible countries through a **four-year donation** program with USAID and JSC Pharmstandard, implemented through the Stop TB Partnership's Global Drug Facility

[jnj.com/TB](https://www.jnj.com/TB)

1. WHO Global Tuberculosis Report 2020. Available here: https://www.who.int/tb/publications/global_report/en/. Last accessed 14 October 2020.

COLLABORATING AT EVERY LEVEL

J&J is taking a holistic approach to ending TB in Southeast Asia through effective case detection, training health care professionals to better manage TB and MDR-TB, raising awareness of TB and reducing stigma among the general public, as well as accelerating affordable access to effective treatment in collaboration with partners.



ACCESS

Donating over 15,000 courses of DR-TB treatment through the donation program in partnership with USAID.



APPROPRIATE USE

Partnering with national TB programs, researchers, health authorities and NGOs across the region to promote appropriate use of our new DR-TB medicine through monitoring and local technical guidelines



MEDICAL EDUCATION

Support capability building in clinical and programmatic DR-TB management for healthcare providers (HCPs) and other TB stakeholders across all countries in the region, reaching more than 4,000 HCPs and other stakeholders



SITE READINESS & MONITORING

Donating a udiometry and ECG machines in 15 high burden areas of Indonesia to improve patient monitoring and provide technical support for both quality and patient care management through liaison officers

PUBLIC EDUCATION & AWARENESS CAMPAIGNS



- **Indonesia:** Partnered with Jakarta provincial government, the National Tuberculosis Program and the media for public education, TB vlog competition and virtual run
- **Philippines:** Partnered with CNN Philippines for *The Story of the Filipino* episode, which gained regional recognition
- **Thailand:** Collaborated with the Tuberculosis Eradication Association for TB patient awareness & supported the National Tuberculosis Program's run for public awareness in 2019

PARTNERSHIPS



- **Indonesia:** Initiated TB Industry Coalition with Stop TB partnership Indonesia, National Tuberculosis Programs, and CSOs to pursue presidential decree for DR-TB care
- **Vietnam:** Partner with PATH to reduce childhood TB morbidity and mortality in high-burden province Nghe An, and continue integrating the program into the National Tuberculosis Program's pediatric strategy
- **Philippines:** Partnered with Aca deme to implement workshops and published a manuscript on the clinical experience of Filipino clinicians with the use of our new DR-TB medicine
- **Myanmar:** Partner with Greenshoot Myanmar for HCP education in Yangon & Mandalay

ABOUT J&J GLOBAL PUBLIC HEALTH

Through a dedicated global public health (GPH) organization that combines R&D, global access strategies and programs, and local operations, Johnson & Johnson is putting the world's most vulnerable and underserved at the heart of everything we do—measuring our success in lives improved. As a team of innovators, we are committed to pioneering and sustainably delivering meaningful and transformation products.

Upholding the rich heritage of Johnson & Johnson, we are taking on the toughest challenges, and, ultimately, we hope to do our part to close the gap of inequity and pave the way to a healthier future for the world's most vulnerable and underserved populations.

